KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 4

Options in First Line Management of Metastatic Pancreatic Cancer and the Determinative Role of ECOG Performance Status

Ferhat Ekinci
Atike Pinar Erdogan
Serkan Yildirim
Ahmet Ozveren
Sayfa
500–507
Yayın Tarihi
2022-11-06
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This difference between the groups was found to be statistically significant (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: It will contribute to the fact that the first-line treatment options of patients with metastatic pancreatic can- cer (PC) who apply to the oncology clinic are discussed in the light of the literature and guide the clinicians in making the initial treatment decision.
📊
Temel Bulgular & Veri:Methods: Patients who were diagnosed with PC in a total of 2 centers between 2010 and 2019 and who were found to have distant organ metastases at the time of diagnosis or during follow-up were included.
💡
Sonuç & Katkı:This difference between the groups was found to be statistically significant (p
🔬Tür:Araştırma Makalesi
📍Kapsam:2010 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: It will contribute to the fact that the first-line treatment options of patients with metastatic pancreatic can- cer (PC) who apply to the oncology clinic are discussed in the light of the literature and guide the clinicians in making the initial treatment decision. Methods: Patients who were diagnosed with PC in a total of 2 centers between 2010 and 2019 and who were found to have distant organ metastases at the time of diagnosis or during follow-up were included. Patients were categorized into 3 groups in terms of metastatic first line treatments: gemcitabine (Gm), gemcitabine-platinum (cisplatin or carbo- platin) (GP) combination and FOLFIRINOX (FX). These three treatment groups were compared in terms of patient with tumor characteristics and progression free survival (PFS) - overall survival (OS). Results: The present study included 355 patients who were admitted to our clinic. The first line therapies received by the patients were analyzed, it was seen that 124 (34.9%) patients received Gm chemotherapy (CT), 43 (12.1%) pa- tients received FX, 138 (38.9%) patients received GP and 18 (5.1%) patients received other regimens. While PFS was 6.1 months in GP areas, it was the shortest with 4.4 months in Gm and the longest with 7.1 months in FX. This difference between the groups was found to be statistically significant (p

🔖

Bu Makaleye Atıf Yap

Ekinci, F., Erdogan, A. P., Yildirim, S., Ozveren, A. (2022). Options in First Line Management of Metastatic Pancreatic Cancer and the Determinative Role of ECOG Performance Status. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 4, 500–507. https://ajindex.com/articles/650394

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021;71:7–33
  2. Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol 2020;JCO2001364
  3. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Seufferlein T, et al. Cancer of the pancreas: ESMO clinical prac- tice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26:56–68
  4. Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin On- col 2019;16:11–26
  5. Shimizu T, Taniguchi K, Asakuma M, Tomioka A, Inoue Y, Kom- eda K, et al. Lymphocyte–to–monocyte ratio and prognostic nutritional index predict poor prognosis in patients on che - motherapy for unresectable pancreatic cancer. Anticancer Res 2019;39:2169–76
  6. Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemo- therapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2006;19:CD002093
  7. Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Gar-rido-Laguna I, et al. Metastatic pancreatic cancer: ASCO clini- cal practice guideline update. J Clin Oncol 2018;36:2545–56
  8. Macarulla T, Pazo-Cid R, Guillén-Ponce C, López R, Vera R, Re- boredo M, et al. Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combina- tion with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2. J Clin Oncol 2019;37:230–8 9. West HJ, Jin JO. JAMA oncology patient page. Performance status in patients with cancer. JAMA Oncol 2015;1:998
  9. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26:56–68
  10. Hidalgo M, Pazo-Cid R, Guillen-Ponce C, Sastre J, Ales I, Re- boredo M, et al. A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of pa- tients with ECOG 2 advanced pancreatic cancer (PDAC). Ann Oncol 2017;28:v212
  11. Manji GA, Olive KP, Saenger YM, Oberstein P. Current and emerging therapies in metastatic pancreatic cancer. Clin Can- cer Res 2017;23:1670–8
  12. Taieb J, Prager GW, Melisi D, Westphalen CB, D'Esquermes N, Ferreras A, et al. First-line and second-line treatment of pa- tients with metastatic pancreatic adenocarci